Skip to content

Studyon the mechanism efficacy and clinical application of artificial tiger bone powder in regulating the osteogenic differentiation of skeletal muscle stem cells for the treatment of osteoporotic fracture in the elderly based on the theory of "disharmony betweenbone andmuscle"

Studyon the mechanism efficacy and clinical application of artificial tiger bone powder in regulating the osteogenic differentiation of skeletal muscle stem cells for the treatment of osteoporotic fracture in the elderly based on the theory of "disharmony betweenbone andmuscle"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000771
Enrollment
Unknown
Registered
2025-04-17
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Senile osteoporotic fracture

Interventions

Control Group:Undergo surgery for intertrochanteric fractures (PFNA or interTAN) and receive routine treatment 6 months postoperatively.
Treatment Group:Undertaking surgery for intertrochanteric fracture of femur (PFNA or interTAN) adding Jintiange capsules on top of conventional treatment 6 months after surgery. Jintiange capsules ar

Sponsors

Linyi People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for osteoporotic intertrochanteric fractures of the femur (2) Male and female patients aged 60 to 90 years old (3) Individuals who were able to walk independently without crutches and have normal hip joint activity before injury (4) Sign the informed consent form and ensure compliance with the trial (5) Those who have not received any other treatment plans

Exclusion criteria

Exclusion criteria: (1) Those who do not meet the diagnostic criteria; (2) Patients with open fractures and soft tissue defects or infections; (3) Those with poor physical condition who are difficult to undergo surgery; (4) Poor compliance and inability to meet follow-up requirements; (5) Those who are in critical condition and find it difficult to make accurate judgments on the effectiveness and safety of new drugs; (6) Individuals with allergies or those who are allergic to the investigational drug; (7) Patients currently taking any other Chinese herbal medicine or preparations containing Chinese herbal ingredients.

Design outcomes

Primary

MeasureTime frame
Excellent rate of fracture healing 6 months after fracture surgery;

Secondary

MeasureTime frame
Bone density testing;Hip Harris Score;bone metabolic markers;Vas Visual Pain Score;X-ray scoring of callus;

Countries

China

Contacts

Public ContactWU LISHENG

Linyi People's Hospital

linyilisheng@163.com17661666716

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026